1,353 Intuitive Surgical, Inc. $ISRG Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 213,027 shares of the medical equipment provider’s stock after selling 1,353 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.06% of Intuitive Surgical worth $86,623,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ISRG. Diversify Advisory Services LLC lifted its stake in Intuitive Surgical by 6.3% in the third quarter. Diversify Advisory Services LLC now owns 27,479 shares of the medical equipment provider’s stock valued at $11,757,000 after purchasing an additional 1,640 shares during the last quarter. Petredis Investment Advisors LLC grew its holdings in Intuitive Surgical by 0.3% during the third quarter. Petredis Investment Advisors LLC now owns 11,634 shares of the medical equipment provider’s stock valued at $4,731,000 after purchasing an additional 35 shares during the period. Miller Financial Services LLC increased its position in Intuitive Surgical by 12.0% in the third quarter. Miller Financial Services LLC now owns 2,084 shares of the medical equipment provider’s stock worth $847,000 after buying an additional 224 shares during the last quarter. Norway Savings Bank increased its position in Intuitive Surgical by 11.3% in the third quarter. Norway Savings Bank now owns 3,619 shares of the medical equipment provider’s stock worth $1,472,000 after buying an additional 366 shares during the last quarter. Finally, Commonwealth Financial Services LLC increased its position in Intuitive Surgical by 15.7% in the third quarter. Commonwealth Financial Services LLC now owns 679 shares of the medical equipment provider’s stock worth $276,000 after buying an additional 92 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Activity

In other news, VP Fredrik Widman sold 1,089 shares of Intuitive Surgical stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the completion of the transaction, the vice president directly owned 1,026 shares in the company, valued at approximately $384,175.44. The trade was a 51.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary S. Guthart sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total value of $4,000,000.00. Following the sale, the director owned 1,245,679 shares in the company, valued at approximately $498,271,600. The trade was a 0.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is currently owned by corporate insiders.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 revenue increased 21.7% year over year to $3.05 billion, surpassing the $2.91 billion consensus estimate, while adjusted earnings of $3.00 per share exceeded expectations of approximately $2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: worldwide procedures grew approximately 15%, including about 14% growth in da Vinci procedures and 31% growth in Ion procedures. System placements also rose to 546 from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Several analysts maintained bullish views or raised targets following the report, including JPMorgan, which lifted its target to $475 and kept an Overweight rating, while Bank of America reiterated Buy with a $470 target. Intuitive Surgical Buy Rating Reaffirmed

Intuitive Surgical Trading Down 2.3%

ISRG opened at $428.12 on Thursday. The company has a 50 day moving average of $393.50 and a 200 day moving average of $408.89. The company has a market cap of $151.25 billion, a PE ratio of 51.77, a price-to-earnings-growth ratio of 3.30 and a beta of 1.46. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 17.70%. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same period in the previous year, the business earned $2.40 EPS. Intuitive Surgical’s revenue was up 21.7% compared to the same quarter last year. Research analysts forecast that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Truist Financial lowered their target price on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. KeyCorp reiterated an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Royal Bank Of Canada cut their price target on Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a research note on Wednesday. Citigroup decreased their price objective on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a report on Friday, July 17th. Finally, UBS Group restated a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. Twenty-five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $500.13.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.